This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GrowGeneration Earnings Miss Estimates in Q3, Revenues Dip Y/Y
by Zacks Equity Research
GRWG expects revenues between $190 million and $195 million for 2024.
Here's What Key Metrics Tell Us About Bunge Global (BG) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Bunge Global (BG) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bunge Global (BG) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bunge Global (BG) delivered earnings and revenue surprises of 5.05% and 1.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Bunge, West Fraser Timber, Hydrofarm and Arcadia Biosciences
by Zacks Equity Research
Bunge, West Fraser Timber, Hydrofarm and Arcadia Biosciences have been highlighted in this Industry Outlook article.
Bunge Global (BG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bunge Global (BG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Agriculture - Products Stocks to Watch Despite Industry Concerns
by Madhurima Das
The near-term outlook for the Zacks Agriculture - Products industry is uncertain due to low commodity prices and inflated costs. Investors should watch BG, WFG, HYFM and RKDA, which are braving the industry headwinds.
Bunge Global Completes Sale of Its 50% Stake in BP Bunge Bioenergia
by Zacks Equity Research
BG completes the sale of its 50% interest in the sugar and bioenergy joint venture to its partner, BP, as it was not core to its long-term strategy.
Is the Options Market Predicting a Spike in Bunge Global (BG) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bunge Global (BG) stock based on the movements in the options market lately.
5 Broker-Favored Stocks Worth a Look in the Current Scenario
by Maharathi Basu
Investors would do well to monitor stocks like AdvanSix (ASIX), Bally's Corporation (BALY), DXC Technology (DXC), Warner Bros. Discovery (WBD) and Bunge (BG) for high returns.
Repsol (REPYY) Taps Honeywell to Boost Biofuels Production
by Zacks Equity Research
Repsol (REPYY) plans to leverage Honeywell's (HON) advanced technologies to transform waste materials like fats, oils, greases, biomass and solids into biofuels and advanced chemicals.
Arcadia Biosciences (RKDA) Q2 Earnings Miss, Increase Y/Y
by Zacks Equity Research
Arcadia Biosciences (RKDA) witnesses a solid 42% improvement in Zola sales in Q2. The company continues to invest to grow the Zola brand through mass market retailers and grocery store chains.
Bunge Global (BG) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bunge Global (BG) delivered earnings and revenue surprises of -3.35% and 3.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Bunge, West Fraser Timber, GrowGeneration and Hydrofarm
by Zacks Equity Research
Bunge, West Fraser Timber, GrowGeneration and Hydrofarm have been highlighted in this Industry Outlook article.
4 Agriculture - Products Stocks to Watch in a Promising Industry
by Madhurima Das
The Agriculture - Products industry is set to gain from solid demand. Stocks like Bunge (BG), WestFraser (WFG), GrowGeneration (GRWG) and Hydrofarm (HYFM) are poised to ride on this positive trend.
Analysts Estimate Bunge Global (BG) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bunge Global (BG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bunge Global (BG) to Sell Its 50% Stake in BP Bunge Bioenergia
by Zacks Equity Research
Bunge Global (BG) to focus on core businesses with the sale of its shares in the BP Bunge Bioenergia joint venture.
Arcadia Biosciences (RKDA) Shares Gain on Q1 Earnings Beat
by Zacks Equity Research
Arcadia Biosciences' (RKDA) Q1 results benefit from a decline in operating expenses.
Company News For May 15, 2024
by Zacks Equity Research
Companies In The Article Are:BG,ENPH, ORCL, PLUG
Should You Invest in the Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS)?
by Zacks Equity Research
Sector ETF report for RSPS
Is Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPS
Earnings Preview: Bunge Global (BG) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bunge Global (BG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repsol (REPYY) and Bunge to Ramp-Up Renewable Fuel Supply
by Zacks Equity Research
Repsol (REPYY) partners with Bunge (BG) to capitalize on the new opportunities to meet the rising demand for lower carbon intensity feedstock used in the production of renewable fuel.
Bunge Global (BG) & Chevron to Build New Facility in Destrehan
by Zacks Equity Research
Bunge Global (BG) and Chevron are set to develop an oilseed processing plant in Destrehan to scale up capabilities.
Should Vanguard Small-Cap Value ETF (VBR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VBR
Bear of the Day: Archer Daniels Midland (ADM)
by Andrew Rocco
Archer Daniels Midland, currently a Zacks Rank #5 (Strong Sell), faces significant challenges as an accounting investigation into its nutrition segment prompts a nearly 25% drop in its stock value. Additionally, health concerns are contributing to decreased demand for ADM's plant-based products.